Oklahoma is currently home to 947 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Oklahoma City, Tulsa, Norman and Edmond. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
NCT06316297
Recruiting
The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of one or two intramuscular injections of the Acne mRNA vaccine candidate at three dose levels in adult participants aged 18 to 45 years with moderate to severe acne in the US.
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
04/25/2024
Locations: Lynn Health Science Institute (LHSI) Site Number : 8400004, Oklahoma City, Oklahoma
Conditions: Acne
Register for Updates
A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C
NCT06119581
Recruiting
The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: University of Oklahoma Health Sciences Center, Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, Oklahoma
Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Register for Updates
A Study to Access the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
NCT05972044
Recruiting
FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with ADHD.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/25/2024
Locations: Clinical Research Site, Oklahoma City, Oklahoma
Conditions: ADHD
Register for Updates
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
NCT05936567
Recruiting
This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatments.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2024
Locations: Vital Prospects Clinical Research Institute, Pc Vpcri, Tulsa, Oklahoma
Conditions: Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
Register for Updates
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
NCT05934526
Recruiting
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/25/2024
Locations: INTEGRIS Cardiovascular Physicians, LLC, Oklahoma City, Oklahoma
Conditions: Pulmonary Arterial Hypertension
Register for Updates
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
NCT05839041
Recruiting
Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
04/25/2024
Locations: Retina Vitreous Center, Edmond, Oklahoma
Conditions: Geographic Atrophy of the Macula, Macular Degeneration
Register for Updates
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
NCT05755438
Recruiting
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/25/2024
Locations: Central Sooner Research, Norman, Oklahoma
Conditions: Prurigo
Register for Updates
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT05554367
Recruiting
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Pancreatic Carcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Register for Updates
Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
NCT05405114
Recruiting
This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination of two medicines (decitabine-tetrahydrouridine). Both medicines are new for the treatment of sickle cell disease. Participants who are not taking Hydroxyurea (HU) will get NDec, NDec and placebo, or placebo. Participants who are on HU treatment before joining the study will get NDec, NDec and placebo, or continue on HU. Which treatment participants g... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Univ Oklahoma HSC_Okla City, Oklahoma City, Oklahoma
Conditions: Sickle Cell Disease
Register for Updates
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
NCT05277571
Recruiting
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2024
Locations: Up0110 104, Oklahoma City, Oklahoma
Conditions: Atopic Dermatitis
Register for Updates
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216
Recruiting
This is a Phase 2/3 study evaluating the safety and efficacy of DM199 in treating participants presenting within 24 hours of Acute Ischemic Stroke (AIS) onset for whom fibrinolytics and/or a catheter-based procedure, mechanical thrombectomy (MT), are not medically appropriate or available due to constraints of clot location, comorbidity risks, and/or time from estimated onset of stroke. The double-blinded study will be randomized, placebo controlled at up to approximately 100 sites.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Ascension St. John, Tulsa, Oklahoma
Conditions: Acute Stroke, Ischemic Stroke, Stroke
Register for Updates
Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT04704921
Recruiting
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, b... Read More
Gender:
All
Ages:
Between 50 years and 89 years
Trial Updated:
04/25/2024
Locations: Retina Vitreous Center (RVC), Edmond, Oklahoma
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV
Register for Updates